Minerva Neurosciences Inc. (NERV) announced Thursday morning that its Phase IIb trial of MIN-101 in patients with negative symptoms of schizophrenia met its primary and secondary endpoints.
from RTT - Before the Bell http://ift.tt/25lZjSt
via IFTTT
No comments:
Post a Comment